EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma

Şule Çalışkan Kamış iD, Metin Çil iD, Emel Koçyiğit Deveci iD, Zeynel Abidin Taş iD, Begül Yağcı iD

BioMed Research International · 2026-01 · 2026 (1)

DOI: 10.1155/bmri/4420962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, online erschienen am 09.04.2026. Verfasst von Şule Çalışkan Kamış und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Osteosarcoma, Sarcoma, Ewing. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study is aimed at evaluating the relationship between preoperative 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F‐FDG PET/CT) findings and histopathological necrosis rates following chemotherapy in patients diagnosed with osteosarcoma (OST) and Ewing sarcoma (EWS).

Methods

Patients diagnosed with OST and EWS between 2017 and 2023 were retrospectively analyzed. Data recorded included preoperative 18 F‐FDG PET/CT findings, demographic characteristics, histopathological diagnosis, maximum standardized uptake value at diagnosis (SUVmax1), maximum standardized uptake value after neoadjuvant chemotherapy (SUVmax2), the SUVmax change ratio (SUVmax2/SUVmax1 = SCR), and the percentage of tumor necrosis in resected specimens.

Results

A total of 49 patients (33 OST and 16 EWS) were included, consisting of 22 females (44.9%) and 27 males (55.1%) with a median age of 12 years (range: 4–20). Median SUVmax1, SUVmax2, and SCR values were 6.8 (0–22.5), 2.5 (0–9.42), and 0.38 (0–1.44), respectively. The median tumor necrosis percentage was 20% (range: 0–100). Stratification according to SUVmax2 (< 2.5 vs. ≥ 2.5) revealed no significant difference in necrosis percentage ( p = 0.234). No significant correlation was observed between SCR and necrosis percentage ( p = 0.102). However, a significant inverse correlation was found between SUVmax2 and necrosis percentage in the overall cohort ( p = 0.040, r = –0.295), which was more pronounced in OST patients ( p = 0.014, r = –0.426).

Conclusion

18 F‐FDG PET/CT is a valuable imaging modality for predicting histopathological response in solid tumors. Consistent with adult studies, our findings demonstrate that post‐NACT FDG uptake is inversely correlated with tumor necrosis percentage, particularly in pediatric OST patients. These results highlight the potential of 18 F‐FDG PET/CT as a noninvasive prognostic tool to assist in early identification of poor responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18OsteosarcomaSarcoma, EwingBone NeoplasmsHumansFemaleChildAdolescentMaleNecrosisChild, PreschoolYoung AdultRetrospective StudiesRadiopharmaceuticals

Stichwörter der Autor:innen

18F-FDG PET/CTEwing sarcomaSUVmaxosteosarcomatumor necrosis percentage

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr.
  • Department of Nuclear Medicine, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr.
  • Department of Medical Pathology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr.

ORCID-Profile: Şule Çalışkan Kamış, Metin Çil, Emel Koçyiğit Deveci, Zeynel Abidin Taş, Begül Yağcı

Zitieren

APA

Kamış, Ş. Ç., Çil, M., Deveci, E. K., Taş, Z. A., & Yağcı, B. (2026). SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/4420962

Vancouver

Kamış ŞÇ, Çil M, Deveci EK, Taş ZA, Yağcı B. SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/4420962

BibTeX
@article{Kam2026,
  author = {Kamış, Şule Çalışkan and Çil, Metin and Deveci, Emel Koçyiğit and Taş, Zeynel Abidin and Yağcı, Begül},
  title = {SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma},
  journal = {BioMed Research International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/bmri/4420962}
}
Kostenlos starten →